Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape. Founded in 2022 by Population Health Partners and ARCH Venture Partners, Metsera has raised $290 million in financing from leading healthcare investors and is based in New York City.
Location: United States, New York
Employees: 11-50
Total raised: $290M
Investors 4
| Date | Name | Website |
| 16.09.2024 | ARCH Ventu... | archventur... |
| 22.08.2024 | F-Prime Ca... | fprimecapi... |
| 16.08.2024 | SymBiosis | symbiosis.... |
| 08.08.2024 | Newpath Ma... | newpath.pa... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 18.04.2024 | - | $290M | - |
Mentions in press and media 3
| Date | Title | Description |
| 28.09.2024 | ARCH Venture Partners: $3+ Billion New Fund Raised To Invest In Next-Gen Biotech Companies | ARCH Venture Partners announced the closing of ARCH Venture Fund XIII, a venture capital fund with over $3 billion to support the founding and growth of early-stage biotechnology companies. ARCH invests in early-stage companies that prevent... |
| 18.04.2024 | Metsera Launches With $290M in Funding | Metsera, a NYC-based clinical-stage biopharmaceutical company, raised $290M in funding. The round was led by ARCH Venture Partners with participation from other healthcare investors including F-Prime Capital, GV, Mubadala Capital, Newpath P... |
| - | Metsera | “Metsera is a clinical-stage biopharmaceutical company dedicated to leading the next generation of medicines and solutions for obesity and metabolic diseases.” |